Laura A.
Laura A. Banaszynski, New York, NY US
Patent application number | Description | Published |
---|---|---|
20100034777 | Method for Regulating Protein Function in Cells In Vivo Using Synthetic Small Molecules - Methods and compositions for the rapid and reversible destabilizing of specific proteins in vivo using cell-permeable, synthetic molecules are described. | 02-11-2010 |
20140010791 | METHODS FOR REGULATING PROTEIN FUNCTION IN CELLS IN VIVO USING SYNTHETIC SMALL MOLECULES - Methods and compositions for the rapid and reversible destabilizing of specific proteins in vivo using cell-permeable, synthetic molecules are described. | 01-09-2014 |
Laura A. Flanagan-Kent, Decatur, GA US
Patent application number | Description | Published |
---|---|---|
20120031870 | BLOW MOLDING METHOD AND APPARATUS FOR FORMING SQUEEZABLE PLASTIC CONTAINER - A blow-molding method for forming a squeezable or tubular plastic container is provided. The method includes molding a preform having a sidewall, an interior cavity, an open end, a closed end, and a neck adjacent the closed end of the preform. The neck of the preform has an engagement structure. The method includes providing a blow mold system including a blow mold cavity. The method includes placing at least a portion of the preform into the blow mold cavity, and blow molding a one-piece container body from the preform by inflating the preform within the blow mold cavity. The container body has an open end, a closed end and a neck adjacent to the closed end. Wherein the open end of the container body is formed from the open end of the preform, and the closed end of the container body is formed from the closed end of the preform. The method includes creating a dispensing opening through the closed end of the container body. | 02-09-2012 |
20140021658 | BLOW MOLDING METHOD AND APPARATUS FOR FORMING SQUEEZABLE PLASTIC CONTAINER - A blow-molding method for forming a squeezable or tubular plastic container is provided. The method includes molding a preform having a sidewall, an interior cavity, an open end, a closed end, and a neck adjacent the closed end of the preform. The neck of the preform has an engagement structure. The method includes providing a blow mold system including a blow mold cavity. The method includes placing at least a portion of the preform into the blow mold cavity, and blow molding a one-piece container body from the preform by inflating the preform within the blow mold cavity. The container body has an open end, a closed end and a neck adjacent to the closed end. Wherein the open end of the container body is formed from the open end of the preform, and the closed end of the container body is formed from the closed end of the preform. The method includes creating a dispensing opening through the closed end of the container body. | 01-23-2014 |
Laura A. Hill, Lisburn, Co Antrim GB
Patent application number | Description | Published |
---|---|---|
20160002732 | MOLECULAR DIAGNOSTIC TEST FOR CANCER - Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test identifies cancer subtypes that have an up-regulation or a down-regulation in biomarker expression related to angiogenesis and vascular development. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any anti-angiogenic agent. This test may be used in different cancer types and with different drugs that directly or indirectly affect angiogenesis or angiogenesis signalling. In addition, the present invention may be used as a prognostic indicator for certain cancer types. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen. | 01-07-2016 |
Laura A. Hill, Lisburn GB
Patent application number | Description | Published |
---|---|---|
20140031260 | Molecular Diagnostic Test for Cancer - Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test defines a novel DNA damage repair deficient molecular subtype and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any chemotherapy. This test may be used in different cancer types and with different drugs that directly or indirectly affect DNA damage or repair, such as many of the standard cytotoxic chemotherapeutic drugs currently in use. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen. | 01-30-2014 |
20140342924 | Molecular Diagnostic Test for Cancer - Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test identifies cancer subtypes that are responsive to anti-angiogenesis therapeutics and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any anti-angiogenic agent. This test may be used in different cancer types and with different drugs that directly or indirectly affect angiogenesis or angiogenesis signalling. In addition, the present invention may be used as a prognostic indicator for certain cancer types. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen. | 11-20-2014 |
Laura A. Johnson, Ann Arbor, MI US
Patent application number | Description | Published |
---|---|---|
20140187521 | AMELIORATION OF INTESTINAL FIBROSIS AND TREATMENT OF CROHN'S DISEASE - Methods of treating patients with inflammatory bowel disease, intestinal fibrosis, or Crohn's disease involve administering a therapeutic amount of CARD-024 or related compound. | 07-03-2014 |
Laura A. Kiefer-Liptak, Elkins, NH US
Patent application number | Description | Published |
---|---|---|
20080226833 | RADIATION CURABLE INK COMPOSITIONS AND APPLICATIONS THEREOF - Radiation curable ink compositions that include a curable component having a functionality that is greater than two, is present in the ink composition in an amount greater than 30 percent by weight, and has a molecular weight in the range of about 400 g/mole to about 10,000 g/mole; a component that has a functionality that is less than or equal to 2; and an initiator component. A solvent component, pigment, a surface tension modifier and other materials also can be included. The radiation curable inks are employed in ink jet printers and are particularly suited for use in printing on large-scale substrates. The printed images described herein have good adhesion to polymeric substrates such as styrene-based, polycarbonates, polyolefins, polyethylene terephthalate glycol ester, acrylic and others. | 09-18-2008 |
Laura A. Knauth, Portland, OR US
Patent application number | Description | Published |
---|---|---|
20110161639 | Event counter checkpointing and restoring - A method of one aspect may include storing an event count of an event counter that counts events that occur during execution within a logic device. The method may further include restoring the event counter to the stored event count after the event counter has counted additional events. Other methods are also disclosed. Apparatus, systems, and machine-readable medium having software are also disclosed. | 06-30-2011 |
20120030518 | LAST BRANCH RECORD INDICATORS FOR TRANSACTIONAL MEMORY - In one embodiment, a processor includes an execution unit and at least one last branch record (LBR) register to store address information of a branch taken during program execution. This register may further store a transaction indicator to indicate whether the branch was taken during a transactional memory (TM) transaction. This register may further store an abort indicator to indicate whether the branch was caused by a transaction abort. Other embodiments are described and claimed. | 02-02-2012 |
20120227045 | METHOD, APPARATUS, AND SYSTEM FOR SPECULATIVE EXECUTION EVENT COUNTER CHECKPOINTING AND RESTORING - An apparatus, method, and system are described herein for providing programmable control of performance/event counters. An event counter is programmable to track different events, as well as to be checkpointed when speculative code regions are encountered. So when a speculative code region is aborted, the event counter is able to be restored to it pre-speculation value. Moreover, the difference between a cumulative event count of committed and uncommitted execution and the committed execution, represents an event count/contribution for uncommitted execution. From information on the uncommitted execution, hardware/software may be tuned to enhance future execution to avoid wasted execution cycles. | 09-06-2012 |
20120311307 | Method And Apparatus For Obtaining A Call Stack To An Event Of Interest And Analyzing The Same - In one embodiment, a processor includes a performance monitor including a last branch record (LBR) stack to store a call stack to an event of interest, where the call stack is collected responsive to a trigger for the event. The processor further includes logic to control the LBR stack to operate in a call stack mode such that an entry to a call instruction for a leaf function is cleared on return from the leaf function. Other embodiments are described and claimed. | 12-06-2012 |
20130262837 | PROGRAMMABLE COUNTERS FOR COUNTING FLOATING-POINT OPERATIONS IN SMD PROCESSORS - A processor includes an execution unit to execute instructions, where each operand of each executed instruction has one or more elements of an element size and at least one operand of the instruction corresponds to a register of a register size. The processor further includes a counter configured to count a number of instructions that have been executed by the execution unit associated with a particular combination of register size and element size. | 10-03-2013 |
20130332933 | PERFORMANCE MONITORING RESOURCES PROGRAMMED STATUS - A system and method for a performance monitoring hardware unit that may include logic to poll one or more performance monitoring shared resources and determine a status of each performance monitoring shared resource. The performance monitoring hardware unit may also include an interface to provide the status to allow programming of the one or more performance monitoring shared resource. The status may correspond to a usage and/or an errata condition. Thus, the performance monitoring hardware unit may prevent programming conflicts of the one or more performance monitoring shared resources. | 12-12-2013 |
20140095814 | Memory Renaming Mechanism in Microarchitecture - A processor includes a processing unit including a storage module having stored thereon a table for tracking physical registers in which each store operation stores source data and a memory renaming module for register renaming load operations based on the table. | 04-03-2014 |
20140095838 | Physical Reference List for Tracking Physical Register Sharing - A processor includes a processing unit including a storage module having stored thereon a physical reference list for storing identifications of physical registers that have been referenced by multiple logical registers, and a reclamation module for reclaiming physical registers to a free list based on a count of each of the physical registers on the physical reference list. | 04-03-2014 |
20140258695 | Last Branch Record Indicators For Transactional Memory - In one embodiment, a processor includes an execution unit and at least one last branch record (LBR) register to store address information of a branch taken during program execution. This register may further store a transaction indicator to indicate whether the branch was taken during a transactional memory (TM) transaction. This register may further store an abort indicator to indicate whether the branch was caused by a transaction abort. Other embodiments are described and claimed. | 09-11-2014 |
20150089286 | EVENT COUNTER CHECKPOINTING AND RESTORING - Event counter checkpointing and restoring is disclosed. In one implementation, a processor includes a first event counter to count events that occur during execution within the processor, event counter checkpoint logic, communicably coupled with the first event counter, to store, prior to a transactional execution of the processor, a value of the first event counter, a second event counter to count events prior to and during the transactional execution, wherein the second event counter is to increment without resetting after the transactional execution is aborted, event count restore logic to restore the first event counter to the stored value after the transactional execution is aborted, and tuning logic to determine, in response to aborting of the transactional execution, a number of the events that occurred during the transactional execution based on the stored value of the first event counter and a value of the second event counter. | 03-26-2015 |
Laura A. Long, San Mateo, CA US
Patent application number | Description | Published |
---|---|---|
20150120418 | SYSTEMS AND METHODS TO PROVIDE REWARDS BASED ON PURCHASED ITEMS - A system includes a POS terminal configured to store a list of products/items eligible for rewards and/or discounts, check items purchased by a user via a transaction against the list to identify items eligible for rewards and/or discounts, aggregate the eligible items according to reward/discount categories, and provide information about the eligible items aggregated according to the categories in an authorization request for the transaction in a payment account of the user. The system further includes a transaction handler receiving the authorization request that contains the information aggregated according to the categories, and provide rewards and/or discounts to the transaction during the authorization and/or settlement of the transaction. | 04-30-2015 |
Laura A. Matott, East Aurora, NY US
Patent application number | Description | Published |
---|---|---|
20090312627 | Radio-labeled ingestible capsule - A method of determining the location of an ingested capsule comprising the steps of providing an ingestible capsule ( | 12-17-2009 |
20100130837 | Modular ingestible capsule - A modular ingestible capsule ( | 05-27-2010 |
20110152639 | TETHERING CAPSULE SYSTEM - A capsule system comprising a first capsule ( | 06-23-2011 |
Laura A. Pinegar, Long Beach, CA US
Patent application number | Description | Published |
---|---|---|
20090318520 | USE OF ISOINDOLES FOR THE TREATMENT OF NEUROBEHAVIORAL DISORDERS - The present invention generally relates to the use of drugs for the treatment of neurobehavioral disorders or symptoms of a neurobehavioral disorder associated with dysfunction of the trimonoamine modulating system (TMMS). More specifically, the invention describes methods for the treatment of a neurobehavioral disorder and/or treatment or prevention of symptoms of a neurobehavioral disorder by administering suitable Isoindole derivatives alone or in combination with other agents so as to provide relatively equal inhibitory effect on serotonin, dopamine and norepinephrine transporters. | 12-24-2009 |
Laura A. Rudolph-Owen, Medford, MA US
Patent application number | Description | Published |
---|---|---|
20080241133 | Novel 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 molecules and uses therefor - The invention provides isolated nucleic acids molecules, designated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 gene has been introduced or disrupted. The invention still further provides isolated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 proteins, fusion proteins, antigenic peptides and anti-25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided. | 10-02-2008 |
20090263860 | Novel 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 and 32252 molecules and uses therefor - The invention provides isolated nucleic acids molecules, designated 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 and 32252 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 and 32252 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 or 32252 gene has been introduced or disrupted. The invention still further provides isolated 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 or 32252 proteins, fusion proteins, antigenic peptides and anti-13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 or 32252 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided. | 10-22-2009 |
20090269350 | Novel 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 10A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC1C, NARC 1A, NARC 25, 86604 and 32222 molecules and uses therefor - The invention provides isolated nucleic acids molecules and proteins, designated 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 20A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC 1A, NARC 25, 86604 and 32222 nucleic acid molecules and proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing said nucleic acid molecules, host cells into which the expression vectors have been introduced, nonhuman transgenic animals in which a said genes have been introduced or disrupted, fusion proteins, antigenic peptides and antibodies to said proteins. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided. | 10-29-2009 |
20100092941 | 32142,21481,25964,21686, Novel dehydrogenase molecules and uses therefor - The invention provides isolated nucleic acids molecules, designated DHDR nucleic acid molecules, which encode novel DHDR-related dehydrogenase molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing DHDR nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DHDR gene has been introduced or disrupted. The invention still further provides isolated DHDR proteins, fusion proteins, antigenic peptides and anti-DHDR antibodies. Diagnostic methods utilizing compositions of the invention are also provided. | 04-15-2010 |
20100150901 | 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206, and 8843 molecules and uses therefor - The invention provides isolated nucleic acids molecules, designated 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 gene has been introduced or disrupted. The invention still further provides isolated 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 proteins, fusion proteins, antigenic peptides and anti-26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided. | 06-17-2010 |
20100291099 | NOVEL 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 10A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC 1A, NARC 25, 86604 AND 32222 MOLECULES AND USES THEREFOR - The invention provides isolated nucleic acids molecules and proteins, designated 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 20A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC 1A, NARC 25, 86604 and 32222 nucleic acid molecules and proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing said nucleic acid molecules, host cells into which the expression vectors have been introduced, nonhuman transgenic animals in which a said genes have been introduced or disrupted, fusion proteins, antigenic peptides and antibodies to said proteins. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided. | 11-18-2010 |
20110150860 | NOVEL 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 AND 49933 MOLECULES AND USES THEREFOR - The invention provides isolated nucleic acids molecules, designated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 gene has been introduced or disrupted. The invention still further provides isolated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 proteins, fusion proteins, antigenic peptides and anti-25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided. | 06-23-2011 |
20110182879 | NOVEL HUMAN TRANSFERASE FAMILY MEMBERS AND USES THEREOF - The invention provides isolated nucleic acids molecules, designated 33877, 47179, 26886, 46743, 27417, 32252, and 53320 nucleic acid molecules, which encode novel human transferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33877, 47179, 26886, 46743, 27417, 32252, or 53320 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33877, 47179, 26886, 46743, 27417, 32252, or 53320 gene has been introduced or disrupted. The invention still further provides isolated 33877, 47179, 26886, 46743, 27417, 32252, or 53320 proteins, fusion proteins, antigenic peptides and anti-33877, 47179, 26886, 46743, 27417, 32252, or 53320 antibodies. Diagnostic methods utilizing compositions of the invention are also provided. | 07-28-2011 |
Laura A. Sanders, Johns Creek, GA US
Patent application number | Description | Published |
---|---|---|
20150153482 | AMPHIPHILIC POLYSILOXANE PREPOLYMERS AND USES THEREOF - The present invention provides an amphiphilic polysiloxane prepolymer which comprises hydrophilic monomeric units derived from at least one hydrophilic vinylic monomer, polysiloxane crosslinking units derived from at least one polysiloxane crosslinker having at least two terminal ethylenically-unsaturated groups, dangling polysiloxane chains each of which is terminated with one ethylenically unsaturated group, and chain-transfer units derived from a chain transfer agent other than a RAFT agent. A prepolymer of the invention is suitable for making hydrogel contact lenses. The present invention is also related to hydrogel contact lenses made from an amphiphilic polysiloxane prepolymer of the invention and to processes for preparing an amphiphilic polysiloxane prepolymer of the invention and for making silicone hydrogel contact lenses. | 06-04-2015 |
Laura A. Schuresko, Santa Cruz, CA US
Patent application number | Description | Published |
---|---|---|
20120231996 | Phalloidin derivatives and methods for their synthesis - The invention provides a cyclomonomer having actin-binding activity. The cyclomonomer is of utility for the study of the molecular biology of actin polymerization. The cyclomonomer is also useful for the study of and treatment of the toxic effects of | 09-13-2012 |
Laura A. Sovey-Strah, Broadview Heights, OH US
Patent application number | Description | Published |
---|---|---|
20120233917 | POLE PLANTER - A pole planter assembly to be secured about a pole. The pole planter includes first and second independent chambers pivotally connected for growing plants. Each of the first and second chambers have wall sections with at least one inward indented surface and at least one outward projecting surface, and the wall sections of the first and second chambers are arranged whereby the at least one outward projecting surface of the wall section of the first chamber is arranged to fit within the corresponding at least one inward indented surface of the wall section of the second chamber to secure the first and second two chambers together. Each of the wall sections have concave surfaces to form a hollow shaped opening through the planter assembly when the first and second chambers are secured together to receive a pole. | 09-20-2012 |
Laura A. Vella-Geynisman, Pittsburgh, PA US
Patent application number | Description | Published |
---|---|---|
20110280897 | POLYPEPTIDES AND USES THEREOF - The invention provides a polypeptide having a sequence comprising from 10 to 24 consecutive amino acids from residues 215-233 of the sequence of human cyclin B1 protein or homolog thereof, as well as a nucleic acid molecule encoding the polypeptide, and compositions thereof. The invention also provides a method for using such polypeptides, nucleic acid molecules, or combinations thereof for treatment or prophylaxis of cancer in patients. | 11-17-2011 |
Laura A. Wejrowski, Dallas, TX US
Patent application number | Description | Published |
---|---|---|
20090139878 | EASY ACCESS AND MULTI-VIEW JEWELRY BOX - A jewelry box and method of storing jewelry is described herein which affords the user a multi-perspective view of the jewelry. The method and box provide a simple means of placing, retrieving, and replacing the desired jewelry without requiring fine dexterity. Rods of the jewelry box readily accommodate user's having conditions such as arthritic immobility or long ornamental finger nails. The present jewelry box is quick and easy to use, while promoting tangle free necklace storage. Fine jewelry chains are protected from tarnish and readily accommodated next to bulky bead-like strands. | 06-04-2009 |
Laura A. Williams, Gurnee, IL US
Patent application number | Description | Published |
---|---|---|
20140288031 | METHODS OF TREATING HEAVY MENSTRUAL BLEEDING - The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens. | 09-25-2014 |